Page last updated: 2024-12-07
sf 2197
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
matlystatin B: structure given in first source; from Actinomadura atramentaria [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 132321 |
| MeSH ID | M0211234 |
Synonyms (9)
| Synonym |
|---|
| 140923-32-6 |
| 1(2h)-pyridazinebutanamide, tetrahydro-n-hydroxy-6-(((2-methyl-1-(1-oxopropyl)butyl)amino)carbonyl)-gamma-oxo-beta-pentyl- |
| tetrahydro-n-hydroxy-6-(((2-methyl-1-(1-oxopropyl)butyl)amino)carbonyl)-gamma-oxo-beta-pentyl-1(2h)-pyridazinebutanamide |
| sf 2197 |
| sf-2197 |
| matlystatin b |
| 2-[2-(2-amino-2-oxoethyl)heptanoyl]-1-hydroxy-n-(3-methyl-5-oxoheptan-4-yl)diazinane-3-carboxamide |
| DTXSID50930949 |
| 1-hydroxy-2-[2-(2-hydroxy-2-iminoethyl)heptanoyl]-n-(3-methyl-5-oxoheptan-4-yl)-1,2-diazinane-3-carboximidic acid |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.38
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||